Scientists identify novel compound to alleviate pain and itch
In a new study, scientists from the Florida campus of The Scripps Research Institute (TSRI) have identified a possible drug candidate that suppresses pain and itch in animal models. Their new approach also reduces the potential for drug abuse and avoids the most common side effects—sedation and anxiety—of drugs designed to target the nervous system's kappa opioid receptors (KORs).
See Also: Why scratching makes you itch more
"The most significant aspect of the study is that we can preserve itch and pain treatment qualities in a KOR agonist that we developed—triazole 1.1—while avoiding the euphoria associated with narcotic opioids and the dysphoria associated with some other selective KOR agonists," said TSRI Professor Laura Bohn, senior author of the new study.
The research is published in the journal Science Signaling.
Circumventing Side Effects
KORs help regulate the release of the neurotransmitter dopamine. Drugs that target KORs have shown promise as therapeutic candidates because of their efficacy for treating chronic itch and relieving pain. Unlike opioid narcotics that target other opioid receptors, these compounds do not produce a "high" or increased risk of overdose; however, they can deplete the body's supply of dopamine and produce dysphoria and sedation, side effects that have limited their clinical development.
Learn More: Spinal cord neurons that control pain and itch
Bohn's laboratory has pioneered the concept that KOR signaling can be fine-tuned to preferentially activate certain pathways over others so that the receptor signals through G proteins rather than through a protein called β-arrestin2.
In the new study, the researchers used rodent models to compare this kind of "biased" KOR agonist, called triazole 1.1, and a conventional KOR agonist.
They found that triazole 1.1 could indeed circumvent the two side effects of previously developed KOR compounds without decreasing dopamine levels, a property associated with dysphoria and sedation.
"This adds to the mounting evidence that shows analgesic effects can be separated from the sedative and dysphoric effects by altering how the agonist engages the receptor," said TSRI Research Associate Tarsis Brust, first author of the study.
Bohn said the new findings clearly demonstrate that the strategy of developing biased KOR agonists offers a promising new way to treat pain and intractable itch without the potential for abuse.
Note: Material may have been edited for length and content. For further information, please contact the cited source.
Brust TF et al. Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria. Science Signalling, Published November 29 2016. doi: 10.1126/scisignal.aai8441
Freedom of Information Request Reveals Benefits of Blocked MS DrugNews
A drug that is blocked by the EU regulatory system has now been found to improve the quality of life of people with multiple sclerosis (MS), according to a study by Queen Mary University of London (QMUL).READ MORE
Researchers Make Surprising Discovery About How Neurons Talk to Each OtherNews
The new findings, made in fruit flies and mice, challenge the existing dogma about how neurons that release the chemical signal dopamine communicate, and may have important implications for many dopamine-related diseases.READ MORE
Brain Circuit Dedicated to Retrieving Memories Discovered at MITNews
MIT neuroscientists have now shown, for the first time, that recalling a memory requires a “detour” circuit that branches off from the original memory circuit.